-
Mashup Score: 14In Memoriam: C. Norman Coleman, M.D., (1945–2024) - 6 day(s) ago
Mentorship, Partnership, Science, and Kindness Always
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14A joint physics and radiobiology DREAM team vision – Towards better response prediction models to advance radiotherapy - 14 day(s) ago
RT is one of the cornerstones of cancer treatment. However, it comes with inevitable radiation dose to normal tissues. Achieving best possible treatment outcome for individual patients through informed selection of modalities and their careful application requires a quantitative description of their contribution to tumour control and side-effects with the help of models (see Table 1).
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10
PURPOSE In the treatment of non–small-cell lung cancer (NSCLC) with a driver mutation, the role of anti–PD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase III study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP ) in EGFR- or ALK-mutated NSCLC that progressed before TKI therapy. MATERIALS AND METHODS We compared the clinical efficacy of ABCP followed by maintenance therapy with atezolizumab plus bevacizumab with pemetrexed plus carboplatin or cisplatin (PC) followed by pemetrexed maintenance. The primary end point was progression-free survival (PFS). RESULTS A total of 228 patients with activating EGFR mutation (n = 215) or ALK translocation (n = 13) were enrolled from 16 sites in the Republic of Korea and randomly assigned at 2:1 ratio to either ABCP (n = 154) or PC arm (n = 74). The median follow-up duration was 26.1 months (95% CI, 24.7 to 28.2). Objective response rates
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors - 1 month(s) ago
Abstract. A majority of cancer patients receive radiation therapy as part of their treatment regimens whether using external beam therapy or locally-delivered radioisotopes. While often effective, some tumors are inadequately controlled with radiation and radiation therapy has significant short-term and long-term toxicities for cancer survivors. Insights into molecular mechanisms involved in cellular responses to DNA breaks introduced by radiation or other cancer therapies have been gained in recent years and approaches to manipulate these responses to enhance tumor cell killing or reduce normal tissue toxicity are of great interest. Here, we report the identification and initial characterization of XRD-0394, a potent and specific dual inhibitor of two DNA damage-response kinases, ATM and DNA-PKcs. This orally bioavailable molecule demonstrates significantly enhanced tumor cell kill in the setting of therapeutic ionizing irradiation in vitro and in vivo. XRD-0394 also potentiates the e
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
PLANNING TIMELINE Please review the guidelines on this page, and on the Call for Abstracts document prior to submission. All submitted abstracts (Scientific / ECI / SIT) for the 70th Annual Meeting of the Radiation Research Society will be be accepted from March 11th through April 17th. Submit abstracts for consideration using the Oasis Submission Site. Please use the links below to view the Call for Abstracts and access the Oasis Submission Site (opening March 11th). Abstract Review Process: All abstracts
Source: www.radres.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18
Approximately 20% to 25% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease (TNM eighth edition).1,2 Every patient should be discussed in a multidisciplinary tumor board to review the staging (extent of nodal involvement and mediastinal invasion) and whether a tumor is resectable. Subsequent choices regarding treatment can be very challenging.3 For patients not eligible for surgery, the standard of care is concurrent chemoradiotherapy (CCRT) followed by adjuvant durvalumab.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14Harvard Radiation Oncology Program - 2017-2018 Roster - 3 month(s) ago
The roster for the 2015 – 2016 Harvard Radiation Oncology Residency Program. Please contact us for more information regarding the program or our residents.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14Harvard Radiation Oncology Program - 2017-2018 Roster - 3 month(s) ago
The roster for the 2015 – 2016 Harvard Radiation Oncology Residency Program. Please contact us for more information regarding the program or our residents.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 33A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer - 3 month(s) ago
Primary tumor failure is common in patients treated with chemoradiation (CRT) for locally-advanced NSCLC (LA-NSCLC). Stereotactic body radiation therapy (SBRT) yields high rates of primary tumor control (PTC) in early-stage NSCLC. This trial tested an SBRT boost to the primary tumor prior to the start of CRT to improve PTC.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Evolving Role of Proton Radiation Therapy in Clinical Practice - 3 month(s) ago
With the expansion of proton radiation therapy centers across the United States and a gradually expanding body of academic evidence supporting its use, more patients are receiving—and asking about—proton therapy than ever before. Here, we outline, for nonradiation oncologists, the theoretical benefits of proton therapy, the clinical evidence to date, the controversies affecting utilization, and the numerous randomized trials currently in progress. We also discuss the challenges of researching and delivering proton therapy, including the cost of constructing and maintaining centers, barriers with insurance approval, clinical situations in which proton therapy may be approached with caution, and the issue of equitable access for all patients. The purpose of this review is to assist practicing oncologists in understanding the evolving role of proton therapy and to help nonradiation oncologists guide patients regarding this technology.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
In Memoriam: C. Norman Coleman, M.D. (1945–2024) Touching and inspiring homage in @RadiotherapyOn1 🙏 @_MichaelBaumann @PBlanchardMD @theNCI @NCICTEP_ClinRes ➡️https://t.co/jXFecQ7JBm